scholarly journals Botox- the wonder poisonous healer

2021 ◽  
Vol 9 (2) ◽  
pp. 57-62
Author(s):  
Komal Kaur Saroya ◽  
Kavipal Singh ◽  
Nimish Sethi ◽  
Simrat Kaur
Keyword(s):  
Botulinum Toxin ◽  
Temporomandibular Disorders ◽  
Botulinum Toxin A ◽  
Medical Applications ◽  
Botulinum Toxins ◽  
Frey’S Syndrome ◽  
Toxin A ◽  
Frey's Syndrome ◽  
Dental Conditions

Botulinum toxin A has a wide variety of medical applications, which are related to the blockade of acetylcholine and often are associated with abnormal muscle contractures. The use of botulinum toxins has also revolutionised the treatment of various dental conditions like bruxism, gummy smiles, Frey’s syndrome spastic disorders, hypersalivation, orthodontic relapse, facial dystonias and temporomandibular disorders. The list of possible new indications is rapidly expanding. Many of these conditions are discussed with regard to their treatment with Botox compared to conventional treatments.

Treatment of gustatory sweating (Frey's syndrome) with botulinum toxin A

Head & Neck ◽  
2003 ◽  
Vol 25 (8) ◽  
pp. 624-628 ◽  
Author(s):  
Andr� Eckardt ◽  
Christian Kuettner
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Frey’S Syndrome ◽  
Toxin A ◽  
Gustatory Sweating ◽  
Frey's Syndrome

S148 – Botulinum Toxin A for the Management of Gustatory Sweating

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P126-P126 ◽  
Author(s):  
Purushotam Sen ◽  
Michael Papesch
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
The Other ◽  
Cochrane Library ◽  
Safe Procedure ◽  
Frey’S Syndrome ◽  
Toxin A ◽  
Duration Of Symptoms ◽  
Gustatory Sweating ◽  
Frey's Syndrome

Objectives To review systematically the evidence currently available on the use of botulinum toxin A in the management of gustatory sweating. Methods We conducted a systematic search of databases including PubMed (1950-December 2007), EMBASE (1966–2007), MEDLINE (1950–2007) and Cochrane library (up to December 2007). The terms used in the search included treatment, Frey's syndrome, gustatory sweating, Botulinum toxin, Botox, Dysport. Data extraction and study evaluation were performed independently by 2 reviewers and results were pooled quantitatively. Data collected included demographic details of patients, aetiology of Frey's syndrome (parotid pathology), duration of symptoms, units of injection, number of injections, commercial types of Botulinum toxin A, rate of recurrence, complications, and length of follow-up. Results There are 2 prospective studies that compared doses of Botulinum toxin (one randomized and the other non-randomized) in the management of gustatory sweating (Frey's syndrome). The other studies included prospective and retrospective case series and case reports. Pooled results from these studies on a total of 239 patients showed that the rate of recurrence or incomplete resolution of symptoms were dose-dependent. Response to treatment did not vary with the size of the affected area or parotid pathology. The demographical details did not differ in the patients with recurrence compared to those patients who were symptom-free. Complications were also not dose-related. Conclusions Botulinum toxin A is a highly effective, minimally invasive, and safe procedure for the treatment of gustatory sweating.

Role of medical thermography in treatment of Frey's syndrome with botulinum toxin A

2014 ◽  
Vol 52 (1) ◽  
pp. 90-92 ◽  
Author(s):  
Richard James Green ◽  
Simon Endersby ◽  
John Allen ◽  
James Adams
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Frey’S Syndrome ◽  
Toxin A ◽  
Frey's Syndrome

scholarly journals The prevention and management of Frey's syndrome and a step by step guide through the nonsurgical treatment with Botulinum toxin

2020 ◽  
Author(s):  
Lukas Fiedler
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Treatment Options ◽  
Frey’S Syndrome ◽  
Direct Response ◽  
Toxin A ◽  
Frey's Syndrome ◽  
Parasympathetic Neurons ◽  
Aberrant Regeneration ◽  
Non Surgical Treatment

Firstly described by Lucy Frey in 1923 the “Frey’s syndrome” is characterized by sweating and flushing in direct response to mastication. The mechanism is aberrant regeneration of postganglionic parasympathetic neurons from the auriculotemporal nerve and Acetylcholine secretion by a masticatory stimulus. This entity occurs in up to 65% following lateral parotid resections and less commonly after neck dissection or facelift procedures. This article aims to list possible surgical and non-surgical treatment options of this iatrogenic entity but should focus on the treatment with botulinum toxin A and provide a step by step guide from the Lugol-Iodine-Starch test to the botulinum toxin A (BoNTA-ONA) injection within the affected area.

scholarly journals The prevention and management of Frey's syndrome and a step by step guide through the nonsurgical treatment with Botulinum toxin

2020 ◽  
Author(s):  
Lukas S Fiedler
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Treatment Options ◽  
Frey’S Syndrome ◽  
Direct Response ◽  
Toxin A ◽  
Frey's Syndrome ◽  
Parasympathetic Neurons ◽  
Aberrant Regeneration ◽  
Non Surgical Treatment

Firstly described by Lucy Frey in 1923 the “Frey’s syndrome” is characterized by sweating and flushing in direct response to mastication. The mechanism is aberrant regeneration of postganglionic parasympathetic neurons from the auriculotemporal nerve and Acetylcholine secretion by a masticatory stimulus. This entity occurs in up to 65% following lateral parotid resections and less commonly after neck dissection or facelift procedures. This article aims to list possible surgical and non-surgical treatment options of this iatrogenic entity but should focus on the treatment with botulinum toxin A and provide a step by step guide from the Lugol-Iodine-Starch test to the botulinum toxin A (BoNTA-ONA) injection within the affected area.

Botulinum toxin A for quality of life improvement in post-parotidectomy gustatory sweating (Frey's syndrome)

2008 ◽  
Vol 122 (10) ◽  
pp. 1100-1104 ◽  
Author(s):  
D M Hartl ◽  
M Julieron ◽  
A-M LeRidant ◽  
F Janot ◽  
P Marandas ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Frey’S Syndrome ◽  
Toxin A ◽  
Social And Emotional ◽  
Gustatory Sweating ◽  
Functional Quality ◽  
Frey's Syndrome

AbstractObjective:To measure patient-reported quality of life before and after botulinum toxin A treatment of post-parotidectomy Frey's syndrome (gustatory sweating).Patients and methods:A questionnaire concerning functional, social and emotional aspects of Frey's syndrome (14 questions, with responses on a zero to three point scale) was administered to 17 patients (13 women and four men) before and one month after intradermal injection of botulinum toxin A. Parotidectomy had been performed one to 19 years previously, for benign (n = 10) or malignant (n = 7) tumours, with gustatory sweating occurring a median of 15 months after surgery (range: one month to 14 years). Pre- and post-treatment quality of life scores were compared using Wilcoxon's test (p < 0.05).Results:Patients' reported functional quality of life improved significantly (p = 0.0004). Their social and emotional scores were not significantly modified (p = 0.155 and 0.142, respectively). Seven patients (41 per cent) found the injections painful, but all patients said that the effects were beneficial, that they would undergo new injections if necessary and that they would recommend this treatment to other patients. The benefit lasted over 1.5 years for 60 per cent of patients. No correlation was found between duration of the effect and the extent of parotidectomy (p = 0.067).Conclusions:Botulinum toxin A significantly improved patients' functional quality of life, without significant improvement in their social or emotional quality of life, according to our questionnaire results. The duration of the effect was longer than the reported physiological effect of botulinum toxin A on acetylcholine receptors.

Frey's syndrome: treatment with botulinum toxin

1997 ◽  
Vol 111 (9) ◽  
pp. 839-844 ◽  
Author(s):  
A. Bjerkhoel ◽  
O. Trobbe
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Surgical Techniques ◽  
Frey’S Syndrome ◽  
Need For Treatment ◽  
Gustatory Sweating ◽  
Parotid Surgery ◽  
Frey's Syndrome ◽  
Before And After ◽  
Set Up

AbstractFrey's syndrome, i.e. gustatory sweating on the cheek, is a fairly common embarrassment after parotid gland surgery. New surgical techniques have been proposed to avoid this complication, but are not widely in use. Hence, there is need for treatment of Frey's syndrome. All surgical and topical treatments have drawbacks. This study was set up in order to evaluate a recently described treatment. One hundred and two patients were interviewed after parotidectomy. Thirty-one of them had noticed gustatory sweating and 15 patients underwent Minor's starch iodine test before, and after, treatment with intracutaneous injections of botulinum toxin A (Botox®, Allergan Inc., USA). Thirteen of the patients did not experience any gustatory sweating at follow-up (one to 13 months). Minor's starch test showed total disappearance of gustatory sweating in 12 of the 15 treated patients. The only side effect was a discreet, transitory affection of the orbicularis oris muscle in one patient. As this treatment is minimally invasive it could be an attractive treatment for Frey's syndrome if the effect is maintained. Complaints of local hypoaesthesia and pain were also common after parotid surgery.

Botulinum Toxin Type a for Frey's Syndrome: A Preliminary Prospective Study

1998 ◽  
Vol 107 (1) ◽  
pp. 52-55 ◽  
Author(s):  
Ollivier Laccourreye ◽  
Luca Muscatelo ◽  
Carole Naude ◽  
Brigitte Bonan ◽  
Daniel Brasnu
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Frey’S Syndrome ◽  
Frey's Syndrome ◽  
Valuable Treatment ◽  
Intracutaneous Injection

Fourteen patients with severe Frey's syndrome (occurring after conservative parotidectomy) managed with intracutaneous injection of botulinum toxin type A were prospectively evaluated. Results were analyzed for effectiveness, complications, and adverse effects. Complications were not encountered. The only adverse effect noted was a temporary and slight partial paresis of the upper lip of 3 months' duration in 2 patients. Permanent paresis was not encountered. Frey's syndrome was always controlled within 2 days following the intracutaneous injection of botulinum toxin A. Frey's syndrome recurrence was not encountered with a follow-up duration that varied from 3 to 9 months (mean follow-up 7 months). This preliminary report confirmed that in patients who have Frey's syndrome after conservative parotidectomy, the intracutaneous injection of botulinum toxin is a valuable treatment option that should be further investigated.

Sign in / Sign up

Export Citation Format

Share Document